P2.03a-057 Ligand Mediated Solid Lipid Nanoparticle of Paclitaxel for Effective Management of Bronchogenic Carcinoma: Topic: Clinical Trials

Abstract

Lung cancer is a disease of uncontrolled cell growth in tissues of lung. It is most common cause of cancer-related deaths in men and second most common in women. It is responsible for 1.3 million deaths worldwide annually. Most common cause is long term exposure to tobacco smoke. The occurrence of lung cancer in nonsmokers, who accounts 15% cases, attributed to combination of genetic factors, radon gases, and asbestos and air pollution including second hand smoke. The treatment and management of diseases associated with lung is difficult with presently available therapeutic systems, as insufficient drug reaches to lung due to mucociliary clearance of the medicament. The proposed drug delivery system was used to determine targeting efficiency of optimized formulation via conjugation of ligand ie Solid Lipid Nanoparticles (SLNs) bearing paclitaxel anchored with lactoferrin molecules. These systems may enhance the drug delivery to lung via receptor mediated endocytosis mechanism. The SLNs were prepared by modified Solvent Injection Method, and then sonicated and finally ligand anchored. The nanoparticles were characterized in-vitro for their shape and size by Scanning (SEM) & Transmission Electron Microscopic (TEM), drug entrapment, in-vitro drug release and stability. The in-vivo study comprised of biodistribution studies in various organs and fluorescence microscopy was performed. The Sulforhodamine Blue (Srb) Colorimetric Assay was performed on human lung cancer cell line (BEAS-2B) For Cytotoxicity Screening. The in-vitro & in-vivo studies result shows a more specific delivery of the Paclitaxel to the Lung. The cell cytotoxicity studies states that Lactoferrin coupled SLN deliver the drug more specifically and have low toxicity effect over the unconjugated SLN and plain drug solution. This study suggests that loading another drug will open new and exciting gateways in the management of other lung diseases. Our finding should be helpful for possible exploitation of lactoferrin as future ligand for the delivery of the drugs for treatments of other lungs diseases.